Misplaced Pages

Bezuclastinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
Bezuclastinib
Clinical data
Other namesCGT-9486, PLX-9486
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 4,5-dimethyl-N-(2-phenyl-1H-pyrrolopyridin-5-yl)-1H-pyrazole-3-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC19H17N5O
Molar mass331.379 g·mol
3D model (JSmol)
SMILES
  • CC1=C(NN=C1C(=O)NC2=CN=C3C(=C2)C=C(N3)C4=CC=CC=C4)C
InChI
  • InChI=1S/C19H17N5O/c1-11-12(2)23-24-17(11)19(25)21-15-8-14-9-16(22-18(14)20-10-15)13-6-4-3-5-7-13/h3-10H,1-2H3,(H,20,22)(H,21,25)(H,23,24)
  • Key:NVSHVYGIYPBTEZ-UHFFFAOYSA-N

Bezuclastinib is an investigational new drug that is being evaluated for the treatment of solid tumors and systemic mastocytosis. It acts as an inhibitor of KIT (a specific type of receptor tyrosine kinase).

References

  1. "Bezuclastinib - Cogent Biosciences". AdisInsight. Springer Nature Switzerland AG.
  2. Farmer I, Radia DH (August 2024). "Systemic Mastocytosis: State of the Art". Current Hematologic Malignancy Reports. doi:10.1007/s11899-024-00737-8. PMID 39187708.
  3. Wagner AJ, Severson PL, Shields AF, Patnaik A, Chugh R, Tinoco G, et al. (September 2021). "Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial". JAMA Oncology. 7 (9): 1343–1350. doi:10.1001/jamaoncol.2021.2086. PMC 8267845. PMID 34236401.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: